Vaccine Approaches To Protect against Group A Streptococcal Pharyngitis

Vincent A. Fischetti

doi:10.1128/9781555816513.ch10

Chapter 10 : Vaccine Approaches To Protect against Group A Streptococcal Pharyngitis

Author: Vincent A. Fischetti

Content Type: Reference

Publication Year: 2006

Category: Bacterial Pathogenesis

Book DOI: 10.1128/9781555816513

Chapter DOI: 10.1128/9781555816513.ch10

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:

Vaccine Approaches To Protect against Group A Streptococcal Pharyngitis, Page 1 of 2

< Previous page | Next page > /docserver/preview/fulltext/10.1128/9781555816513/9781555813437_Chap10-1.gif /docserver/preview/fulltext/10.1128/9781555816513/9781555813437_Chap10-2.gif

Abstract:

Streptococcus pyogenes (Lancefield group A) is a human pathogen responsible for a wide range of diseases, the most common of which are nasopharyngeal infections and impetigo. About 3% of individuals with untreated or inadequately treated streptococcal pharyngitis develop rheumatic fever and rheumatic heart disease, a sequela of the streptococcal infection resulting in cardiac damage, particularly to the mitral valve. This chapter concentrates on the progress to date toward the development of a vaccine to protect against streptococcal nasopharyngeal infection. It was shown more than 50 years ago that the surface M protein would be a prime candidate for a vaccine to protect against streptococcal infection. The chapter describes type-specific protection, multivalent type-specific vaccine, mucosal vaccine for non-type-specific protection, passive protection, active immunization with conserved-region peptides, and the use of gram-positive commensals as vaccine vectors. In addition, it discusses non-M-protein approaches to protect against streptococcal infection. Perhaps a combination vaccine incorporating the serum opsonic power of the polyvalent type-specific approach combined with the mucosal protection offered by a mucosal vaccine will ultimately be the best way to control all pathogenic aspects of a streptococcus.

Citation: Fischetti V. 2006. Vaccine Approaches To Protect against Group A Streptococcal Pharyngitis, p 113-122. In Fischetti V, Novick R, Ferretti J, Portnoy D, Rood J (ed), Gram-Positive Pathogens, Second Edition. ASM Press, Washington, DC. doi: 10.1128/9781555816513.ch10

Key Concept Ranking

M Protein: 0.59623027
Enzyme-Linked Immunosorbent Assay: 0.45401636
Streptococcus pyogenes: 0.43973914
Streptococcus gordonii: 0.4368837

0.59623027

Highlighted Text: Show | Hide

Full text loading...

Figures

Vaccine Approaches To Protect against Group A Streptococcal Pharyngitis

[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555816513.chap10-1,webId=/content/author/10.1128/9781555816513.chap10-1,properties={foaf_givenname=Vincent A., foaf_name=Vincent A. Fischetti, foaf_surname=Fischetti}]]

/content/10.1128/9781555816513.chap10.fig10-1

FIGURE 1

Proposed model of the M protein from M6 strain D471 ( 23a , 29 ). The coiled-coil rod region extends about 60 nm from the cell wall with a short nonhelical domain at the NH2 terminus. The Pro/Gly-rich region of the molecule is found within the peptidoglycan ( 44a ). The membrane-spanning segment is composed of predominantly hydrophobic amino acids, and a short charged tail extends into the cytoplasm. Data suggest that the membrane anchor may be cleaved shortly after synthesis ( 44a ). The A-, B-, and C-repeat regions are indicated along with those segments containing conserved, variable, and hypervariable epitopes among heterologous M serotypes. Pepsin designates the position of a pepsin-susceptible site near the center of the molecule.

10.1128/9781555816513/fig10-1_thmb.gif

10.1128/9781555816513/fig10-1.gif

FIGURE 1

/content/10.1128/9781555816513.chap10.fig10-2

FIGURE 2

The extent of colonization and death of mice challenged with group A streptococci after oral immunization with M-protein conserved-region M6 peptides linked to CTB. Throats of orally immunized mice were swabbed each day after challenge with M14 streptococci, and the specimens were plated on blood plates to determine the extent of colonization compared with that of mice vaccinated with CTB only. Plates showing group A streptococci were scored as positive.

10.1128/9781555816513/fig10-2_thmb.gif

10.1128/9781555816513/fig10-2.gif

FIGURE 2

/content/10.1128/9781555816513.chap10.fig10-3

FIGURE 3

The extent of colonization and death of mice challenged with group A streptococci after oral immunization with recombinant vaccinia virus containing the gene for the whole conserved region of the M6 protein. Throats of orally immunized mice were swabbed each day after challenge with M14 streptococci, and the specimens were plated on blood plates to determine the extent of colonization compared with that of mice vaccinated with wild-type vaccinia only. Plates showing group A streptococci were scored as positive.

10.1128/9781555816513/fig10-3_thmb.gif

10.1128/9781555816513/fig10-3.gif

FIGURE 3

/content/10.1128/9781555816513.chap10.fig10-4

FIGURE 4

M protein-specific salivary IgA in rabbits colonized with S. gordonii expressing the conserved region on the cell surface. Salivary samples were taken after pylocarpine induction and tested in an enzyme-linked immunosorbent assay against the M protein.

10.1128/9781555816513/fig10-4_thmb.gif

10.1128/9781555816513/fig10-4.gif

FIGURE 4

/content/10.1128/9781555816513.chap10.fig10-5

FIGURE 5

M protein-specific serum IgG in rabbits colonized with S. gordonii expressing the conserved region on the cell surface. Blood samples were taken at weekly intervals and tested in ELISA against the M protein.

10.1128/9781555816513/fig10-5_thmb.gif

10.1128/9781555816513/fig10-5.gif

FIGURE 5

References

/content/book/10.1128/9781555816513.chap10

1. Beachey, E. H.,, G. H. Stollerman,, R. H. Johnson,, I. Ofek,, and A. L. Bisno. 1979. Human immune response to immunization with a structurally defined polypeptide fragment of streptococcal M protein. J. Exp. Med. 150: 862– 877.

2. Beachey, E. H.,, J. M. Seyer,, J. B. Dale,, W. A. Simpson,, and A. H. Kang. 1981. Type-specific protective immunity evoked by synthetic peptide of Streptococcus pyogenes M protein. Nature 292: 457– 459.

3. Beachey, E. H.,, H. Gras-Masse,, A. Tarter,, M. Jolivet,, F. Audibert,, L. Chedid,, and J. M. Seyer. 1986. Opsonic antibodies evoked by hybrid peptide copies of types 5 and 24 streptococcal M proteins synthesized in tandem. J. Exp. Med. 163: 1451– 1458.

4. Beall, B.,, R. Facklam,, and T. Thompson. 1995. Sequencing emm-specific polymerase chain reaction products for routine and accurate typing of group A streptococci. J. Clin. Microbiol. 34: 953– 958.

5. Bessen, D.,, and V. A. Fischetti. 1988. Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci. Infect. Immun. 56: 2666– 2672.

6. Bessen, D.,, and V. A. Fischetti. 1988. Passive acquired mucosal immunity to group A streptococci by secretory immunoglobulin A. J. Exp. Med. 167: 1945– 1950.

7. Bessen, D.,, and V. A. Fischetti. 1990. Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes. J. Immunol. 145: 1251– 1256.

8. Bessen, D.,, K. F. Jones,, and V. A. Fischetti. 1989. Evidence for two distinct classes of streptococcal M protein and their relationship to rheumatic fever. J. Exp. Med. 169: 269– 283.

9. Brandt, E. R.,, W. A. Hayman,, B. Currie,, J. Carapetis,, Y. Wood,, D. C. Jackson,, J. Cooper,, W. D. Melrose,, A. J. Saul,, and M. F. Good. 1996. Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci. Immunology 89: 331– 337.

10. Bronze, M. S.,, D. S. McKinsey,, E. H. Beachey,, and J. B. Dale. 1988. Protective immunity evoked by locally administered group A streptococcal vaccines in mice. J. Immunol. 141: 2767– 2770.

11. Byrd, C. M.,, T. C. Bolken,, K. F. Jones,, T. K. Warren,, A. T. Vella,, J. McDonald,, D. King,, Z. Blackwood,, and D. E. Hruby. 2002. Biological consequences of antigen and cytokine co-expression by recombinant Streptoccocus gordonii vaccine vectors. Vaccine 20: 2197– 2205.

12. Challacombe, S. J.,, D. Rahman,, H. Jeffery,, S. S. Davis,, and D. T. O’Hagan. 1992. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology 76: 164– 168.

13. Cleary, P. P.,, U. Prahbu,, J. B. Dale,, D. E. Wexler,, and J. Handley. 1992. Streptococcal C5a peptidase is a highly specific endopeptidase. Infect. Immun. 60: 5219– 5223.

14. Courtney, H. S.,, D. L. Hasty,, and J. B. Dale. 2003. Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci. Infect. Immun. 71: 5097– 5103.

15. D’Alessandri, R.,, G. Plotkin,, R. M. Kluge,, M. K. Wittner,, E. N. Fox,, A. Dorfman,, and R. H. Waldman. 1978. Protective studies with group A streptococcal M protein vaccine. III. Challenge of volunteers after systemic or intranasal immunization with type 3 or type 12 group A Streptococcus. J. Infect. Dis. 138: 712– 718.

16. Dale, J. B.,, E. Y. Chiang,, and J. W. Lederer. 1993. Recombinant tetravalent group A streptococcal M protein vaccine. J. Immunol. 151: 2188– 2194.

17. Dale, J. B.,, R. W. Baird,, H. S. Courtney,, D. L. Hasty,, and M. S. Bronze. 1994. Passive protection of mice against group A streptococcal pharyngeal infection by lipoteichoic acid. J. Infect. Dis. 169: 319– 323.

18. Dale, J. B.,, M. Simmons,, E. C. Chiang,, and E. Y. Chiang. 1996. Recombinant, octavalent group A Streptococcal M protein vaccine. Vaccine 14: 944– 948.

19. Dale, J. B.,, P. P. Cleary,, V. A. Fischetti,, J. M. Musser,, and J. B. Zabriskie. 1997. Group A and group B streptococcal vaccine development. A round table presentation. Adv. Exp. Med. Biol. 418: 863– 868.

20. Dodu, S. R. A.,, and S. Bothig. 1989. Rheumatic fever and rheumatic heart disease in developing countries. World Health Forum 10: 203– 212.

21. Dunn, L. A.,, D. J. McMillan,, M. Batzloff,, W. Zeng,, D. C. J. Jackson,, J. A. Upcroft,, and P. Upcroft. 2002. Parenteral and mucosal delivery of a novel multi-epitope M protein-based group A streptococcal vaccine construct: investigation of immunogenicity in mice. Vaccine 20: 2635– 2640.

22. Eldridge, J. H.,, J. K. Staas,, J. A. Meulbroek,, J. R. McGhee,, T. R. Tice,, and R. M. Gilley. 1991. Biodegradable microspheres as a vaccine delivery system. Mol. Immunol. 28: 287– 294.

23. Fischetti, V. A. 1989. Streptococcal M protein: molecular design and biological behavior. Clin. Microbiol. Rev. 2: 285– 314.

23a.. Fischetti, V. A.,, D. A. D. Parry,, B. L. Trus,, S. K. Hollingshead,, J. R. Scott,, and B. N. Manjula. Conformational characteristics of the complete sequence of group A streptococcal M6 proteins. Proteins 3: 60– 69.

24. Fischetti, V. A.,, W. M. Hodges,, and D. E. Hruby. 1989. Protection against streptococcal pharyngeal colonization with a vaccinia: M protein recombinant. Science 244: 1487– 1490.

25. Fischetti, V. A.,, V. Pancholi,, and O. Schneewind. 1990. Conservation of a hexapeptide sequence in the anchor region of surface proteins of gram-positive cocci. Mol. Microbiol. 4: 1603– 1605.

26. Fox, E. N. 1974. M proteins of group A streptococci. Bacteriol. Rev. 38: 57– 86.

27. Good, M. F.,, P. J. Cleary,, J. Dale,, V. A. Fischetti,, K. Fuchs,, H. Sabharwal,, and J. Zabriskie,. 2004. Development of a vaccine to prevent infection with group A streptococci and rheumatic fever, p. 695– 710. In M. M. Levine,, J. B. Kaper,, R. Rappuoli,, M. A. Liu,, and M. F. Good (ed.), New Generation Vaccines. Marcel Dekker, Inc., New York, N.Y.

28. Harbaugh, M. P.,, A. Podbielski,, S. Hugl,, and P. P. Cleary. 1993. Nucleotide substitutions and small-scale insertion produce size and antigenic variation in group A streptococcal M1 protein. Mol. Microbiol. 8: 981– 991.

29. Hollingshead, S. K.,, V. A. Fischetti,, and J. R. Scott. 1986. Complete nucleotide sequence of type 6 M protein of the group A streptococcus: repetitive structure and membrane anchor. J. Biol. Chem. 261: 1677– 1686.

30. Horstmann, R. K.,, H. J. Sievertsen,, M. Leippe,, and V. A. Fischetti. 1992. Role of fibrinogen in complement inhibition by streptococcal M protein. Infect. Immun. 60: 5036– 5041.

31. Hu, M. C.,, M. A. Walls,, S. D. Stroop,, M. A. Reddish,, B. Beall,, and J. B. Dale. 2002. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect. Immun. 70: 2171– 2177.

32. Ji, Y.,, L. McLandsborough,, A. Kondagunta,, and P. P. Cleary. 1996. C5a peptidase alters clearance and trafficking of group A streptococci by infected mice. Infect. Immun. 64: 503– 510.

33. Ji, Y.,, B. Carlson,, A. Kondagunta,, and P. P. Cleary. 1997. Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus. Infect. Immun. 65: 2080– 2087.

34. Jones, K. F.,, and V. A. Fischetti. 1988. The importance of the location of antibody binding on the M6 protein for opsonization and phagocytosis of group A M6 streptococci. J. Exp. Med. 167: 1114– 1123.

35. Jones, K. F.,, B. N. Manjula,, K. H. Johnston,, S. K. Hollingshead,, J. R. Scott,, and V. A. Fischetti. 1985. Location of variable and conserved epitopes among the multiple serotypes of streptococcal M protein. J. Exp. Med. 161: 623– 628.

36. Jones, K. F.,, S. K. Hollingshead,, J. R. Scott,, and V. A. Fischetti. 1988. Spontaneous M6 protein size mutants of group A streptococci display variation in antigenic and opsonogenic epitopes. Proc. Natl. Acad. Sci. USA 85: 8271– 8275.

37. Kapur, V.,, J. T. Maffei,, R. S. Greer,, L. L. Li,, G. J. Adams,, and J. M. Musser. 1994. Vaccination with streptococcal extracellular cysteine protease (interleukin-1 beta convertase) protects mice against challenge with heterologous group A streptococci. Microb. Pathol. 16: 443– 450.

38. Kotloff, K. L.,, M. Corretti,, K. Palmer,, J. D. Campbell,, M. A. Reddish,, M. C. Hu,, S. S. Wasserman,, and J. B. Dale. 2004. Safety and immunogenicity of a recombinant multivalent group A streptococcal vaccine in healthy adults. JAMA 292: 709– 715.

39. Lancefield, R. C. 1959. Persistence of type specific antibodies in man following infection with group A streptococci. J. Exp. Med. 110: 271– 292.

40. Lancefield, R. C. 1962. Current knowledge of the type specific M antigens of group A streptococci. J. Immunol. 89: 307– 313.

41. McKenzie, S. J.,, and J. F. Halsey. 1984. Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response. J. Immunol. 133: 1818– 1824.

42. Medaglini, D.,, G. Pozzi,, T. P. King,, and V. A. Fischetti. 1995. Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium Streptococcus gordonii after oral colonization. Proc. Natl. Acad. Sci. USA 92: 6868– 6872.

43. Navarre, W. W.,, and O. Schneewind. 1994. Proteolytic cleavage and cell wall anchoring at the LPXTG motif of surface proteins in gram-positive bacteria. Mol. Microbiol. 14: 115– 121.

44. Olive, C.,, T. Clair,, P. Yarwood,, and M. F. Good. 2002. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope. Vaccine 20: 2816– 2825.

44a.. Pancholi, V.,, and V. A. Fischetti. 1988. Isolation and characterization of the cell-associated region of group A streptococcal M6 protein. J. Bacteriol. 170: 2618– 2624.

45. Penney, T. J.,, D. R. Martin,, L. C. Williams,, S. A. de Malmanche,, and P. L. Bergquist. 1995. A single emm gene-specific oligonucleotide probe does not recognise all members of the Streptococcus pyogenes M type 1. FEMS Microbiol. Lett. 130: 145– 150.

46. Polly, S. M.,, R. H. Waldman,, P. High,, M. K. Wittner,, A. Dorfman,, and E. N. Fox. 1975. Protective studies with a group A streptococcal M protein vaccine. II. Challenge of volunteers after local immunization in the upper respiratory tract. J. Infect. Dis. 131: 217– 224.

47. Pozzi, G.,, M. Contorni,, M. R. Oggioni,, R. Manganelli,, M. Tommasino,, F. Cavalieri,, and V. A. Fischetti. 1992. Delivery and expression of a heterologous antigen on the surface of streptococci. Infect. Immun. 60: 1902– 1907.

48. Pruksakorn, S.,, B. Currie,, E. Brandt,, D. Martin,, A. Galbraith,, C. Phornphutkul,, S. Hunsakunachal,, A. Manmontri,, and M. F. Good. 1994. Towards a vaccine for rheumatic fever: identification of a conserved target epitope on M protein of group A streptococci. Lancet 344: 639– 642.

49. Relf, W. A.,, J. Cooper,, E. R. Brandt,, W. A. Hayman,, R. F. Anders,, S. Pruksakorn,, B. Currie,, A. Saul,, and M. F. Good. 1996. Mapping a conserved conformational epitope from the M protein of group A streptococci. Pept. Res. 9: 12– 20.

50. Salvadori, L. G.,, M. S. Blake,, M. McCarty,, J. Y. Tai,, and J. B. Zabriskie. 1995. Group A streptococcus-liposome ELISA antibody titers to group A polysaccharide and opsonophagocytic capability to the antibodies. J. Infect. Dis. 171: 593– 600.

51. Schulze, K.,, E. Medina,, G. S. Chhatwal,, and C. A. Guzman. 2003. Stimulation of long-lasting protection against Streptococcus pyogenes after intranasal vaccination with non adjuvanted fibronectin-binding domain of the SfbI protein. Vaccine 21: 1958– 1964.

52. Shet, A.,, E. L. Kaplan,, D. R. Johnson,, and P. P. Cleary. 2003. Immune response to group A streptococcal C5a peptidase in children: implications for vaccine development. J. Infect. Dis. 188: 809– 817.

53. Stevens, D. L. 1992. Invasive group A streptococcus infections. Clin. Infect. Dis. 14: 2– 13.

54. Tacket, C. O.,, D. M. Hone,, R. Curtiss III,, S. M. Kelly,, G. Losonsky,, L. Guers,, A. M. Harris,, R. Edelman,, and M. M. Levine. 1992. Comparison of the safety and immunogenicity of delta-aroC delta-aroD and delta-cya delta-crp Salmonella typhi strains in adult volunteers. Infect. Immun. 60: 536– 541.

55. Tartaglia, J.,, and E. Paoletti,. 1990. Live recombinant viral vaccines, p. 125– 151. In M. H. V. van Regenmortel, and A. R. Neurath (ed.), Immunochemistry of Viruses, II. Elsevier Science, New York, N.Y.

56. van de Rijn, I.,, J. B. Zabriskie,, and M. McCarty. 1977. Group A streptococcal antigens cross-reactive with myocardium. Purification of heart-reactive antibody and isolation and characterization of the streptococcal antigen. J. Exp. Med. 146: 579.

57. Veasy, L. G.,, S. E. Wiedmeier,, G. S. Orsmond,, H. D. Ruttenberg,, M. M. Boucek,, S. J. Roth,, and V. F. Tait. 1987. Resurgence of acute rheumatic fever in the intermountain area of the United States. N. Engl. J. Med. 316: 421– 427.

58. Yokoyama, Y., and Harabuchi, Y. 2002. Intranasal immunization with lipoteichoic acid and cholera toxin evokes specific pharyngeal IgA and systemic IgG responses and inhibits streptococcal adherence to pharyngeal epithelial cells in mice. Int. J. Pediatr. Otorhinolaryngol. 63: 235– 241.